Bayonet Tech, Pfizer expects clinical ‘response’ to coronavirus vaccine in late October

Bayonet Tech BNTX,
+ 4.54%
And Pfizer Inc. PFE,
+ 1.00%,
Candidates developing the Covid-19 vaccine said in a news release on Wednesday that they plan to conduct a regulatory review for BNT 162B2 in October based on the success of the vaccine in late-stage clinical trials. However, the companies did not say in which countries they plan to conduct the review. Shares of Bioentech rose 9.9% in pre-market trading on Wednesday, while shares of Pfizer rose 1.3%. “When [Phase 3] The study reads, it is based on several variables but for now, our model, our best case, predicts that we will have the answer by the end of October, ‘Pfizer CEO Albert Borla said on the Today show Tuesday, noting later that it means That the clinical response, not regulatory, was due to news of AstraZeneca’s AZN, as shares of both companies plunged into premarket trading on Wednesday.
-2.46%
AZN,
-1.12%
The coronavirus vaccine trial was suspended due to safety concerns, a company spokesman confirmed. The companies also announced the findings of a previous study of BNT162B2, which was published as a print edition, showing that the vaccine prevents virus infection when injected into macaques. So far this year, Bioentech has 76. 76%, Pfizer shares 3.3 %% and S&P 50000 SPX,
+ 1.08%
3..3%.